Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and GEJ Cancer
NCT05836584Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2023
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Event-free survival at 3 years. Started Dec 2023; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05836584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836584.